Invivyd (IVVD) Revenue (2024 - 2025)
Invivyd (IVVD) posted Revenue of $17.2 million for Q4 2025, up 31.06% on a QoQ basis from $13.1 million in Q3 2025, and up 24.51% year-over-year from $13.8 million in Q4 2024.
Invivyd (IVVD) Revenue (2024 - 2025) Analysis & Trends
Invivyd's Revenue history runs 2 years deep, the most recent figure standing at $17.2 million for Q4 2025.
- Quarterly Revenue rose 24.51% year-over-year to $17.2 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $53.4 million (up 110.47% YoY) and the FY2025 annual result came in at $53.4 million, up 110.47% from the prior year.
- Revenue was $17.2 million for Q4 2025 at Invivyd, up from $13.1 million in the prior quarter.
- Across five years, Revenue topped out at $17.2 million in Q4 2025 and bottomed at $2.3 million in Q2 2024.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Revenue (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 67,102.16 Bn | 67,101.87 Bn | - | - |
| 2 | Nanobiotix | 1,909.44 Bn | 1,909.38 Bn | - | - |
| 3 | Akari Therapeutics | 989.71 Bn | 989.71 Bn | - | - |
| 4 | BeOne Medicines | 471.58 Bn | 466.79 Bn | 1.35 Bn | 1.51 Bn |
| 5 | Vertex Pharmaceuticals | 121.97 Bn | 114.72 Bn | 2.59 Bn | 2.99 Bn |
| 6 | Regeneron Pharmaceuticals | 69.93 Bn | 61.18 Bn | 3.31 Bn | 3.61 Bn |
| 7 | Belite Bio | 62.68 Bn | 62.68 Bn | - | - |
| 8 | Argenx Se | 55.80 Bn | 50.61 Bn | 1.41 Bn | 1.56 Bn |
| 9 | Alnylam Pharmaceuticals | 37.37 Bn | 34.36 Bn | 959.66 Mn | 1.17 Bn |
| 10 | Invivyd | 104.45 Mn | -122.24 Mn | 16.07 Mn | 17.21 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 17.21 Mn |
| Sep 30, 2025 | 13.13 Mn |
| Jun 30, 2025 | 11.79 Mn |
| Mar 31, 2025 | 11.30 Mn |
| Dec 31, 2024 | 13.82 Mn |
| Sep 30, 2024 | 9.30 Mn |
| Jun 30, 2024 | 2.26 Mn |